FIA
VTGN icon

FNY Investment Advisers’s VistaGen Therapeutics VTGN Stock Holding History

FNY Investment Advisers’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,000
Closed -$21K – 1518
2025
Q3 		$21K Buy
+6,000
New +$17.9K 0.01% 676
2023
Q3 		– Sell
-83
Closed – – 766
2023
Q2 		$0 Hold
83
– – ﹤0.01% 715
2023
Q1 		$0 Hold
83
– – ﹤0.01% 754
2022
Q4 		$0 Sell
83
-800
-91% -$3.01K ﹤0.01% 781
2022
Q3 		$4K Buy
883
+850
+2,576% +$8.43K ﹤0.01% 481
2022
Q2 		$0 Buy
+33
New +$1.17K ﹤0.01% 932

Other funds holding VTGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LM
Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

FNY Investment Advisers's VTGN Position: Q4 2025 in Review

FNY Investment Advisers sold out of VistaGen Therapeutics (VTGN) in Q4 2025, closing a stake of 6,000 shares — an estimated $21K sold.

FNY Investment Advisers first reported a position in VTGN in Q2 2022 and held it in 6 quarters. The position peaked at $21K in Q3 2025. 55 funds tracked by Wall St. Rank hold VTGN as of Q4 2025.

  • FNY Investment Advisers reported no remaining VistaGen Therapeutics position as of Q4 2025 after selling out during the quarter.
  • FNY Investment Advisers sold 6,000 VistaGen Therapeutics shares in Q4 2025, an estimated $21K.
  • FNY Investment Advisers first reported a position in VistaGen Therapeutics in Q2 2022 and held it in 6 quarters.
  • FNY Investment Advisers's VistaGen Therapeutics position peaked at $21K in Q3 2025.
  • 55 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q4 2025.

Based on FNY Investment Advisers's 13F filing for Q4 2025, filed 16 Jan 2026.